Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05444894
NCT05444894Active, not recruitingPhase 1

A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)

Editas Medicine, Inc.16 sites in 2 countries9 target enrollmentStarted: April 29, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
9
Locations
16
Primary Endpoint
Proportion of participants achieving engraftment defined as neutrophil engraftment (defined as demonstrating absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L post EDIT-301 infusion for 3 consecutive measurements obtained on different days)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia

Detailed Description

This is a Phase 1/2 single-arm, open-label, multicenter study evaluating the safety, tolerability, and efficacy of a single unit dose of EDIT-301 for autologous hematopoietic stem cell transplant in adult participants with TDT, age 18 to 35 years, inclusive

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 35 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of Transfusion Dependent B-Thalassemia as defined by:
  • •Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/hemoglobin E (HbE) based on historical data in medical records, and
  • •History of at least 100 mL/kg/year or 10 U/year of packed red blood cell (RBC) transfusions in the 2 years prior to signing informed consent
  • •Clinically stable and eligible to undergo autologous HSCT
  • •Karnofsky Performance Status ≥ 70

Exclusion Criteria

  • •Available 10/10 human leukocyte antigen (HLA)-matched related donor
  • •Prior HSCT or contraindications to autologous HSCT
  • •Participants with associated a history of α-thalassemia and > 1 alpha chain deletion, or alpha multiplications as documented in medical records
  • •Participants with a history of other inherited hemoglobinopathy or thalassemic mutation (Hb S, C, D or other) as documented in medical records
  • •Prior receipt of gene therapy
  • •Inadequate bone marrow function, as defined by white blood cell count of < 3 x 10^9/L or a platelet count < 100 x 10^9/L (without hypersplenism), per investigator judgement
  • •Inadequate organ function
  • •Advanced liver disease
  • •Any prior or current malignancy, or immunodeficiency disorder,
  • •Immediate family member with a known or suspected Familial Cancer Syndrome
  • •Clinically significant and active bacterial, viral, fungal, or parasitic infection

Outcomes

Primary Outcomes

Proportion of participants achieving engraftment defined as neutrophil engraftment (defined as demonstrating absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L post EDIT-301 infusion for 3 consecutive measurements obtained on different days)

Time Frame: EDIT-301 infusion (Day 0) to 42 days post EDIT-301 infusion

Frequency and severity of adverse events (AEs) (incidence of AEs and Grade 3 or higher serious adverse events, using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v.5.0)

Time Frame: Screening through up to 24 months post EDIT-301 infusion

Secondary Outcomes

  • Change in the fetal hemoglobin (HbF) concentration compared to baseline overtime(Baseline through up to 24 months post EDIT-301 infusion)
  • Proportion of participants with hemoglobin concentration ≥ 9 g/dL(EDIT-301 infusion (Day 0) through 3, 6, 12 months up to 24 months post EDIT-301 infusion)
  • Proportion of alleles per participant with intended genetic modification present in bone marrow cells over time(EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion)
  • Incidence of all-cause mortality(Screening through up to 24 months post EDIT-301 infusion)
  • Proportion of alleles per participant with intended genetic modification present in peripheral blood over time(EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion)
  • Change in the total hemoglobin concentration compared to baseline overtime(Baseline through up to 24 months post EDIT-301 infusion)
  • Change in parameters of iron overload compared to baseline over time(Baseline through up to 24 months post EDIT-301 infusion)
  • Kinetics of HSPC engraftment(EDIT-301 infusion (Day 0) to first day of 3 consecutive measurements of platelets ≥ 50 x 10^9/L for at least 1 week following the last platelet transfusion and 10 days following thrombopoietin mimetics use up to 24 months post EDIT-301 infusion.)
  • Proportion of participants achieving the sustained transfusion reduction (TR) for at least 6 months and at least 12 months from 3 months post-EDIT-301 infusion(3 months post EDIT-301 infusion through up to 24 months post EDIT-301 infusion)
  • Proportion of participants achieving the sustained transfusion independence (TI) for at least 6 months and, at least 12 months from 3 months post EDIT-301 infusion(3 months through up to 24 months post EDIT-301 infusion)
  • Proportion of participants receiving iron chelation therapy over time(EDIT-301 infusion (Day 0) through up to 24 months post EDIT-301 infusion)
  • Incidence of transplant related mortality(EDIT-301 infusion (Day 0) through Day 100 post EDIT-301 infusion and from EDIT-301 infusion (Day 0) through 12 months post EDIT-301 infusion)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (16)

Loading locations...

Similar Trials

Completed
Phase 3
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial FibrillationAtrial Fibrillation
NCT03683030Biosense Webster, Inc.397
Completed
Phase 3
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)Primary Immune Deficiency
NCT01199705CSL Behring25
Suspended
Phase 3
Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced ChildrenChronic PainPostsurgical Pain
NCT04681027Endo Pharmaceuticals15
Unknown
Not Applicable
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)Alzheimer Disease, Early OnsetAlzheimer DiseaseAlzheimer DementiaMild Cognitive ImpairmentMemory DisordersMemory LossMemory Disorders, Age RelatedAlzheimer Disease, Late OnsetCognitive ImpairmentDementia, MildDementia, Alzheimer TypeCognitive DeclineMemory Impairment
NCT03661034Cognito Therapeutics, Inc.20
Recruiting
Phase 2
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp SystemCardiomyopathiesCardiogenic ShockHeart FailureCongenital Heart Disease
NCT06080074Stanford University50
EDIT-301 for Autologous Hematopoietic Stem... | Clinical Trial